Dynamis Therapeutics, Inc. ("Dynamis") is a biopharmaceutical company that is developing proprietary new drugs to treat chronic inflammatory disease. Its proprietary drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone (3DG). Scientific evidence, including research at the Fox Chase Cancer Center, suggests that elevated 3DG causes metabolic, neurological, and dermatological diseases, ranging from diabetic retinopathy (blindness) and nephropathy (kidney disease) to inflammatory skin conditions and aging. The Company’s first medical products are drugs against dry eye and the complications of diabetes.
Dynamis' lead drug candidate, DYN 15, prevents the formation of 3DG and lowers the levels of several key cytokines that are stimulated in chronic inflammation. The discovery was serendipitous; DYN 15 is a known inactive excipient currently used with marketed drugs. DYN15 has an excellent safety profile. The strategy of developing a known and safe compound for a new use significantly reduces the risk of failure from unexpected side effects. Dynamis has broad patent protection for both the new uses of DYN15 and for other anti-inflammatory compounds that block 3DG.
In order to generate revenues to partially fund the development of Rx products, Dynamis has successfully licensed its technology to cosmetic companies. $4.2 million has been received to date from out-licensing and equity partnerships with Rohto Pharmaceutical Co. in Japan, and a major well-known U.S. consumer products company. Dynamis also introduced a patented anti-aging/anti-wrinkling cosmetic cream, MEG 21, into the professional dermatologist/spa market in 2006.
Unlike most development stage companies, Dynamis has an established revenue stream that is being used to partially fund pre-clinical and clinical development of the Rx products.
|
